99mTc-Pyrophosphate Retention in Atelectatic Pulmonary Tissues of a Patient With Transthyretin Cardiac Amyloidosis.
暂无分享,去创建一个
Yilei Zhou | Yue Wang | Yu Pan | Yifan Zhang | Yun Xi
[1] P. Hawkins,et al. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[2] R. Brunken,et al. Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes , 2018, Journal of Nuclear Cardiology.
[3] A. Wechalekar,et al. Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[4] A. Fernández-Codina,et al. Utility of the 18F-Florbetapir positron emission tomography in systemic amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[5] V. Dilsizian,et al. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction , 2018, Current Cardiology Reports.
[6] J. Goldsmith,et al. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. , 2016, JAMA cardiology.
[7] Zhezhen Jin,et al. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis , 2016, Journal of Nuclear Cardiology.
[8] V. Dilsizian,et al. Molecular Imaging of Amyloidosis: Will the Heart Be the Next Target After the Brain? , 2012, Current Cardiology Reports.